Company: ZLAB
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001704292-25-000024
Chunk: 95

Company: Zai Lab Ltd
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 95
---
2,498)185 %Foreign currency gains 6,422 14,457 (8,035)(56)%9,909 8,281 1,628 20 %Other income (expense), net(508)3,441 (3,949)(115)%3,045 3,859 (814)(21)%Loss before income tax (35,963)(41,671)5,708 (14)%(125,128)(175,419)50,291 (29)%Income tax expense— — — — %— — — — %Net loss(35,963)(41,671)5,708 (14)%(125,128)(175,419)50,291 (29)%

Revenues

Product Revenue, Net

The following table presents net revenue by commercial program ($ in thousands):

Three Months Ended September 30,ChangeNine Months Ended September 30,Change20252024$%20252024$%ZEJULA42,432 48,227 (5,795)(12)%133,002 138,727 (5,725)(4)%VYVGART / VYVGART Hytrulo27,727 27,265 462 2 %72,329 63,617 8,712 14 %NUZYRA15,430 9,997 5,433 54 %44,840 32,205 12,635 39 %OPTUNE12,657 7,715 4,942 64 %36,375 32,779 3,596 11 %QINLOCK8,901 8,643 258 3 %25,946 21,774 4,172 19 %XACDURO6,445 — 6,445 NM12,184 — 12,184 NMAUGTYRO1,677 — 1,677 NM4,702 — 4,702 NMOther (i)92 — 92 NM717 — 717 NMTotal product revenue, net115,361 101,847 13,514 13 %330,095 289,102 40,993 14 %

NM - Not Meaningful

(i)Other includes product candidates sold in patient programs prior to commercialization. 

Our product revenue